000291389 001__ 291389
000291389 005__ 20250512095826.0
000291389 0247_ $$2doi$$a10.1007/s11060-024-04733-z
000291389 0247_ $$2pmid$$apmid:38937309
000291389 0247_ $$2ISSN$$a0167-594X
000291389 0247_ $$2ISSN$$a1573-7373
000291389 0247_ $$2altmetric$$aaltmetric:165519362
000291389 037__ $$aDKFZ-2024-01377
000291389 041__ $$aEnglish
000291389 082__ $$a610
000291389 1001_ $$aGuidara, Souhir$$b0
000291389 245__ $$aCharacteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
000291389 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2024
000291389 3367_ $$2DRIVER$$aarticle
000291389 3367_ $$2DataCite$$aOutput Types/Journal article
000291389 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725284292_17193
000291389 3367_ $$2BibTeX$$aARTICLE
000291389 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291389 3367_ $$00$$2EndNote$$aJournal Article
000291389 500__ $$a2024 Sep;169(2):391-398
000291389 520__ $$aDiffuse midline gliomas (DMG) with H3K27 alterations (H3K27M-DMG) are a highly aggressive form of brain cancer. In rare cases, H3K27 mutations have been observed in diffuse non-midline gliomas (DNMG). It is currently unclear how these tumors should be classified. Herein, we analyze the characteristics of DNMG with H3K27M mutations.We reviewed the clinical, radiological and histological characteristics of all patients with an H3K27M mutated diffuse glioma diagnosed in our institution, between 2016 and 2023, to identify cases with a non-midline location. We then performed a molecular characterization (DNA methylation profiling, whole genome and transcriptome sequencing or targeted sequencing) of patients with an H3K27M-mutant DNMG and reviewed previously reported cases.Among 51 patients (18 children and 33 adults) diagnosed with an H3K27M diffuse glioma, we identified two patients (4%) who had a non-midline location. Including our two patients, 39 patients were reported in the literature with an H3K27M-mutant DNMG. Tumors were most frequently located in the temporal lobe (48%), affected adolescents and adults, and were associated with a poor outcome (median overall survival was 10.3 months (0.1-84)). Median age at diagnosis was 19.1 years. Tumors frequently harbored TP53 mutations (74%), ATRX mutations (71%) and PDGFRA mutations or amplifications (44%). In DNA methylation analysis, H3K27M-mutant DNMG clustered within or close to the reference group of H3K27M-mutant DMG. Compared to their midline counterpart, non-midline gliomas with H3K27M mutations seemed more frequently associated with PDGFRA alterations.DNMG with H3K27M mutations share many similarities with their midline counterpart, suggesting that they correspond to a rare anatomical presentation of these tumors. This is of paramount importance, as they may benefit from new therapeutic approaches such as ONC201.
000291389 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000291389 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291389 650_7 $$2Other$$aDiffuse intrinsic pontine glioma
000291389 650_7 $$2Other$$aDiffuse midline glioma H3 K27-altered
000291389 650_7 $$2Other$$aH3K27M
000291389 650_7 $$2Other$$aH3K28M
000291389 650_7 $$2Other$$aMethylation
000291389 650_7 $$2Other$$aNon-midline
000291389 650_7 $$2Other$$aPediatric glioma
000291389 7001_ $$aSeyve, Antoine$$b1
000291389 7001_ $$aPoncet, Delphine$$b2
000291389 7001_ $$aLeonce, Camille$$b3
000291389 7001_ $$aBringuier, Pierre-Paul$$b4
000291389 7001_ $$aMcLeer, Anne$$b5
000291389 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b6$$udkfz
000291389 7001_ $$aCartalat, Stéphanie$$b7
000291389 7001_ $$aPicart, Thiebaud$$b8
000291389 7001_ $$aFerrari, Anthony$$b9
000291389 7001_ $$aHench, Jürgen$$b10
000291389 7001_ $$aFrank, Stephan$$b11
000291389 7001_ $$aMeyronet, David$$b12
000291389 7001_ $$aDucray, François$$b13
000291389 7001_ $$aBarritault, Marc$$b14
000291389 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-024-04733-z$$n2$$p391-398$$tJournal of neuro-oncology$$v169$$x0167-594X$$y2024
000291389 8564_ $$uhttps://inrepo02.dkfz.de/record/291389/files/s11060-024-04733-z.pdf
000291389 8564_ $$uhttps://inrepo02.dkfz.de/record/291389/files/s11060-024-04733-z.pdf?subformat=pdfa$$xpdfa
000291389 909CO $$ooai:inrepo02.dkfz.de:291389$$pVDB
000291389 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000291389 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000291389 9141_ $$y2024
000291389 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-20$$wger
000291389 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-20$$wger
000291389 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-20$$wger
000291389 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2022$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-20
000291389 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-20
000291389 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000291389 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000291389 980__ $$ajournal
000291389 980__ $$aVDB
000291389 980__ $$aI:(DE-He78)B360-20160331
000291389 980__ $$aI:(DE-He78)HD01-20160331
000291389 980__ $$aUNRESTRICTED